FDA: Drug Trials Snapshot for Tavneos | Source Library

GovernmentU.S. health regulator

Source type: Government
Access type: Official
Publisher: U.S. Food and Drug Administration
Date: 2021-10-07
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

U.S. health regulator

Publisher type: Regulator
Bias profile: Low

This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 98/100; Primary Anchor
Clinical outcomes: 84/100; Strong Support
Mechanism: 68/100; Context Source
Safety: 95/100; Primary Anchor
Consumer context: 68/100; Context Source
Trial discovery: 68/100; Context Source

Best used for

Approvals
Labels
Safety communications

Weak for

Comparative effectiveness
Consumer experience

Used in Viral Vitalism

Regulatory statusbrief1 reference

EMA Recommended Revoking Tavneos Authorization After Data Integrity and Liver Safety Concerns

Roles: Regulatory status

Show section-level references

EMA recommended revoking Tavneos' EU marketing authorization after finding that the main study supporting approval was unreliable and that available evidence did not sufficiently confirm benefit relative to risk.

Regulatory statustimeline1 reference

EMA recommends Tavneos authorization revocation

Roles: Regulatory status

Show section-level references

EMA's reported recommendation put Tavneos into a benefit-risk, liver-safety, and clinical-trial-integrity review lane while final EU action remained pending.

Related studies

No structured study record is currently attached to this source.

Related sources

GovernmentU.S. health regulator

FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies

Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 1 connection

Inspect source ->

GovernmentU.S. health regulator

FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing

Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 1 connection

Inspect source ->

GovernmentU.S. health regulator

FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease

Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 2 connections

Inspect source ->

ArticleGeneral published source

Reuters: EU regulator backs revoking Amgen's right to sell rare-disease drug

Canonicalized from live-fire regulatory medicine batch.

Trust score: 60
Publisher: Reuters
Access: Publisher
Usage: 2 connections

Inspect source ->

ArticleGeneral published source

Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission

Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.

Trust score: 60
Publisher: Regenxbio
Access: Publisher
Usage: 1 connection

Inspect source ->

ArticleGeneral published source

Reuters: FDA reverses course on Regenxbio rare-disease gene therapy

Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.

Trust score: 60
Publisher: Reuters
Access: Publisher
Usage: 2 connections

Inspect source ->

Topic tags

medicinerare-diseaseimmunologydrug-safetyregulatory-watchtavneosavacopananca-associated-vasculitis